Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286641 | 0.86 | GAA (0.66) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL3087061 | 0.84 | GAA (0.73) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL14359694 | 0.83 | GAA (0.61) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL10534529 | 0.81 | GAA (0.59) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL622501 | 0.80 | GAA (0.68) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL10967899 | 0.79 | GAA (0.72) | GAAKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL17358642 | 0.77 | KMT2A (0.57) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL6578808 | 0.77 | GAA (0.63) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL2109312 | 0.77 | GAA (0.63) | GAAKMT2AMEN1MCL1ALDH1A1 | |
| SCHEMBL7126303 | 0.77 | GAA (0.63) | GAAKMT2AMEN1L3MBTL1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808737-A1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | BIAL - Portela & Ca., S.A. (PT) | 2021-04-21 | — | — | EP | disclosed |
| EP-3044215-B1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | BIAL PORTELA & CA SA (PT) | 2020-04-29 | — | — | EP | disclosed |
| US-10059696-B2 | Process for preparing 1,3-dihydroimidazole-2-thione derivatives | BIAL-PORTELA & CA, S.A. (PT) | 2018-08-28 | — | — | US | disclosed |
| EP-2726454-B1 | PROCESS | BIAL-PORTELA & CA S A (PT) | 2018-01-24 | — | — | EP | disclosed |
| EP-2726454-B1 | PROCESS | BIAL-PORTELA & CA S A (PT) | 2018-01-24 | — | — | EP | disclosed |
| US-20160311804-A1 | Process | BIAL-PORTELA & CA, S.A. (PT) | 2016-10-27 | — | — | US | disclosed |
| US-20160311804-A1 | Process | BIAL-PORTELA & CA, S.A. (PT) | 2016-10-27 | — | — | US | disclosed |
| US-20160221981-A1 | Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein | BIAL-PORTELA & CA., S.A. (PT) | 2016-08-04 | — | — | US | disclosed |
| US-9346751-B2 | Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives | BIAL-PORTELA & CA, S.A. (PT) | 2016-05-24 | — | — | US | disclosed |
| US-9346751-B2 | Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives | BIAL-PORTELA & CA, S.A. (PT) | 2016-05-24 | — | — | US | disclosed |
| WO-2015038022-A1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | BIAL - PORTELA & CA., S.A. (PT) | 2015-03-19 | — | — | WO | disclosed |
| US-20140221668-A1 | Process | BIAL-PORTELA & CA, S.A. (PT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221668-A1 | Process | BIAL-PORTELA & CA, S.A. (PT) | 2014-08-07 | — | — | US | disclosed |
| EP-2726454-A2 | PROCESS | Bial-Portela & CA, S.A. (PT) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013002660-A2 | PROCESS | BIAL - PORTELA & Cª, S.A. (PT) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013002660-A2 | PROCESS | BIAL - PORTELA & Cª, S.A. (PT) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059696-B2 | Process for preparing 1,3-dihydroimidazole-2-thione derivatives | DHPS, TPMT, SULT1E1 | GAA 2094/4885KMT2A 2198/4885MEN1 1196/4885 |
| US-20140221668-A1 | Process | DHPS, CYP3A5, SULT1E1 | GAA 963/4885KMT2A 2703/4885MEN1 1090/4885 |
| US-20160221981-A1 | Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein | DBH, COMT, ADRB3 | GAA 661/4885KMT2A 2335/4885MEN1 3274/4885 |
| US-20160311804-A1 | Process | DHPS, CYP3A5, SULT1E1 | GAA 963/4885KMT2A 2703/4885MEN1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.